Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + lenalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
The combination of epcoritamab, lenalidomide, and rituximab is an investigational regimen for the treatment of follicular lymphoma, particularly in relapsed/refractory (R/R) or high-risk patients. Epcoritamab is a subcutaneously administered bispecific monoclonal antibody that binds to CD3 on T cells and CD20 on malignant B cells, redirecting T cells to kill B-cell lymphoma cells. Lenalidomide is an immunomodulatory small molecule that enhances immune cell function and has direct anti-tumor effects. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, leading to their destruction via immune-mediated mechanisms. This triple combination aims to leverage complementary mechanisms for improved efficacy over standard regimens. Clinical trials have shown high response rates and deep remissions in follicular lymphoma patients treated with this regimen[1][2][5][6].
- Brand names
- Epkinly + Rituxan + Revlimid
- Other names
- R2 (for the combination of lenalidomide and rituximab)
02
Targets
Beyond the preview
Go deeper on epcoritamab + lenalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + lenalidomide + rituximab.